Vernal Keratoconjunctivitis – Pipeline Insight, 2020

Vernal Keratoconjunctivitis – Pipeline Insight, 2020

  • September 2020 •
  • 62 pages •
  • Report ID: 5968536 •
  • Format: PDF
“Vernal Keratoconjunctivitis – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Vernal Keratoconjunctivitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Vernal Keratoconjunctivitis Understanding

Vernal Keratoconjunctivitis: Overview
Vernal Keratoconjunctivitis is a severe inflammatory disease that appears in children and adolescents with seasonal recurrence. It is most often seen in boys and tends to resolve at puberty. It is a relatively rare, chronic form of ocular allergy that can cause severe visual complications. Clinically, Vernal Keratoconjunctivitis can be divided into 3 subtypes: conjunctival, limbal, and mixed presentations.

Symptoms
Disease severity seems milder in limbal Vernal Keratoconjunctivitis, leading some to suspect that it is the early presentation of a spectrum of disease. However, there appears to be variability in the prevalence of certain types, based on geography and atopic history, which suggests that the pathogenesis of the two types may be different. The most common symptoms are itching, photophobia, burning, and tearing. The most common signs are giant papillae, superficial keratitis, and conjunctival hyperaemia.

Diagnosis
Differential diagnosis of Vernal Keratoconjunctivitis includes any of the chronic allergic conjunctivitis’s including seasonal allergic conjunctivitis, perennial allergic conjunctivitis, atopic keratoconjunctivitis, or giant papillary conjunctivitis, as well as chlamydial infection, especially in the early stages on the disease. Vernal Keratoconjunctivitis may be differentiated from the above disorders by hypertrophic papillae in the tarsal form of Vernal Keratoconjunctivitis or Horner Trantas dots in the limbal form, or a combination of the two, along with no involvement of the eyelids.

Treatment
There is currently no defined gold-standard treatment algorithm for Vernal Keratoconjunctivitis, but there are many options available, and treatment should be tailored to the individual. Whatever treatment regimen is prescribed, it should be initiated promptly and the patient should be monitored closely for the development of any corneal complications. Therapies that are used for the treatment of Vernal Keratoconjunctivitis include:
• Mast cell stabilizers
• Antihistamines
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Topical corticosteroids
• Cyclosporine
• Tacrolimus
• Other therapies: Corticosteroids or other immunomodulatory agents

Vernal Keratoconjunctivitis Emerging Drugs Chapters
This segment of the Vernal Keratoconjunctivitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vernal Keratoconjunctivitis Emerging Drugs
• Lirentelimab (AK002): Allakos
Lirentelimab is an investigational, non-fucosylated IgG1 monoclonal antibody targeting Siglec-8. By targeting Siglec-8, an inhibitory receptor, lirentelimab blocks multiple inflammatory pathways. In clinical and preclinical studies, binding of lirentelimab to Siglec-8 induces inhibition of mast cells, apoptosis of tissue eosinophils, and depletion of blood eosinophils by antibody dependent cellular cytotoxicity (ADCC). Lirentelimab is being developed in several mast cell and eosinophil driven diseases, and has demonstrated positive clinical activity in eosinophilic gastrointestinal diseases (EGIDs), chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.
Further product details are provided in the report……..

Vernal Keratoconjunctivitis: Therapeutic Assessment
This segment of the report provides insights about the different Vernal Keratoconjunctivitis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Vernal Keratoconjunctivitis
There are approx. 5+ key companies which are developing the therapies for Vernal Keratoconjunctivitis. The companies which have their Vernal Keratoconjunctivitis drug candidates in the early stage, i.e. phase I include, Allakos etc.
Phases
This report covers around 5+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Vernal Keratoconjunctivitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Subcutaneous
• Intravenous
• Oral
• Intramuscular

• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Monoclonal antibodies

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vernal Keratoconjunctivitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vernal Keratoconjunctivitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vernal Keratoconjunctivitis drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Vernal Keratoconjunctivitis R&D. The therapies under development are focused on novel approaches to treat/improve Vernal Keratoconjunctivitis.
• July 2020: Extension study shows efficacy of cyclosporine in treatment of vernal keratoconjunctivitis.
• An 8-month follow-up extension of the Vernal Keratoconjunctivitis Study, or VEKTIS, showed that continuous use of cyclosporine is safe and effective for the treatment of vernal keratoconjunctivitis in children and adolescents.
• The VEKTIS study was originally a 4-month evaluation of the safety and efficacy of cyclosporine A cationic emulsion (CsA CE) 0.1% eye drops administered four times daily (high dose) or twice daily (low dose) vs. vehicle only. One hundred sixty-nine patients between the ages of 4 and 17 years were included.

Vernal Keratoconjunctivitis Report Insights
• Vernal Keratoconjunctivitis Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Vernal Keratoconjunctivitis Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Vernal Keratoconjunctivitis drugs?
• How many Vernal Keratoconjunctivitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vernal Keratoconjunctivitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vernal Keratoconjunctivitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vernal Keratoconjunctivitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Santen SAS
• Allakos, Inc.
• Astellas Pharma Inc.
• Laboratoires Thea

Key Products
• NOVA22007
• AK002
• Cyclosporine
• FK506